Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
from The Medical News http://ift.tt/1Fs3v50
from The Medical News http://ift.tt/1Fs3v50
No comments:
Post a Comment